Sun Pharmaceutical
SUNPHARMA · NSE · Pharma · India
₹1,807.00
-2.1% today
52-week range
₹1,548.00 – ₹1,916.60
Revenue (FY2026)
₹58,462 Cr
Net margin
19.6%
Volume
1,243,362
Ask MarketChacha about SUNPHARMA
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Financials
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2026 | ₹58,462 Cr | ₹11,479 Cr | — | 19.6% | — |
| FY2025 | ₹52,578 Cr | ₹10,929 Cr | — | 20.8% | — |
| FY2024 | ₹48,497 Cr | ₹9,576 Cr | — | 19.7% | — |
| FY2023 | ₹43,886 Cr | ₹8,474 Cr | — | 19.3% | — |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| 2026Q1 | ₹14,612 Cr | ₹2,714 Cr | — | 18.6% | — |
| 2025Q4 | ₹15,521 Cr | ₹3,369 Cr | — | 21.7% | — |
| 2025Q3 | ₹14,478 Cr | ₹3,118 Cr | — | 21.5% | — |
| 2025Q2 | ₹13,851 Cr | ₹2,279 Cr | — | 16.5% | — |
Figures as reported, in ₹ (crore). Source: Yahoo Finance.
Filings & announcements
2026
In the news
- Sun Pharmaceutical fixes record date for ₹5 final dividend - scanx.trade· scanx.trade
- Sun Pharmaceutical Industries fixes record date for final dividend - Business Standard· Business Standard
- Sun Pharma dividend schedule: Board announces record date for ₹5/share final dividend issue - Upstox· Upstox
- Sun Pharmaceutical Industries Ltd drops for fifth straight session - Business Standard· Business Standard
- Stock Picks Today: Hyundai, Pine Labs, ONGC, IndusInd Bank, Sun Pharma And More On Brokerages' Radar - NDTV Profit· NDTV Profit
- Buy Sun Pharmaceutical Industries; target of Rs 2070: Prabhudas Lilladher - Moneycontrol.com· Moneycontrol.com
- Margin pressure, slower growth outlook may cap upside for Sun Pharma stock - The Economic Times· The Economic Times
- Sun Pharma Shares In Focus As Motilal Oswal Retains Bullish Call After Q4 — Check Target Price, Upside - NDTV Profit· NDTV Profit
- Sun Pharma Shares Trade Lower On Mixed Brokerage View Despite Q4 Profit Surge — Check Target Price - NDTV Profit· NDTV Profit
- Sun Pharma shares slip post Q4; analysts cautious on near-term upside - Business Standard· Business Standard
Education and discussion only — not investment advice. Data from official filings (SEC/BSE), Yahoo Finance, and Google News. Verify with the linked sources before acting.